Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1962 Oct 13;87(15):802–807.

The Pathogenesis of Parkinson's Disease: A New Hypothesis

Andre Barbeau
PMCID: PMC1849683  PMID: 13966498

Full text

PDF
802

Images in this article

803Fig. 1a
on p.803
803Fig. 1b
on p.803

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMIN A. H., CRAWFORD T. B., GADDUM J. H. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J Physiol. 1954 Dec 10;126(3):596–618. doi: 10.1113/jphysiol.1954.sp005229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. AYD F. J., Jr A survey of drug-induced extrapyramidal reactions. JAMA. 1961 Mar 25;175:1054–1060. doi: 10.1001/jama.1961.03040120016004. [DOI] [PubMed] [Google Scholar]
  3. BARBEAU A. Dopamine and basal ganglia diseases. Arch Neurol. 1961 Jan;4:97–102. doi: 10.1001/archneur.1961.00450070099011. [DOI] [PubMed] [Google Scholar]
  4. BARBEAU A., JASMIN G. [Determination of urinary 5-hydroxyindolacetic acid in Parkinson's disease]. Rev Can Biol. 1961 Dec;20:837–838. [PubMed] [Google Scholar]
  5. BARBEAU A., MURPHY G. F., SOURKES T. L. Excretion of dopamine in diseases of basal ganglia. Science. 1961 May 26;133(3465):1706–1707. doi: 10.1126/science.133.3465.1706-a. [DOI] [PubMed] [Google Scholar]
  6. BARBEAU A. Preliminary observations on abnormal catecholamine metabolism in basal ganglia diseases. Neurology. 1960 May;10:446–451. doi: 10.1212/wnl.10.5.446. [DOI] [PubMed] [Google Scholar]
  7. BARBEAU A., SOURKES T. L. Some biochemical aspects of extrapyramidal diseases. Rev Can Biol. 1961 Jun;20:197–203. [PubMed] [Google Scholar]
  8. BARTELS E. C., ROHART R. R. The relationship of hyperthyroidism and Parkinsonism. AMA Arch Intern Med. 1958 Mar;101(3):562–568. doi: 10.1001/archinte.1958.00260150050006. [DOI] [PubMed] [Google Scholar]
  9. BERNHEIMER H., BIRKMAYER W., HORNYKIEWICZ O. [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome]. Klin Wochenschr. 1961 Oct 15;39:1056–1059. doi: 10.1007/BF01487648. [DOI] [PubMed] [Google Scholar]
  10. BERTLER A., ROSENGREN E. Occurrence and distribution of dopamine in brain and other tissues. Experientia. 1959 Jan 15;15(1):10–11. doi: 10.1007/BF02157069. [DOI] [PubMed] [Google Scholar]
  11. BIRKMAYER W., HORNYKIEWICZ O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961 Nov 10;73:787–788. [PubMed] [Google Scholar]
  12. CARLSSON A., LINDQVIST M., MAGNUSSON T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957 Nov 30;180(4596):1200–1200. doi: 10.1038/1801200a0. [DOI] [PubMed] [Google Scholar]
  13. CARLSSON A., LINDQVIST M., MAGNUSSON T., WALDECK B. On the presence of 3-hydroxytyramine in brain. Science. 1958 Feb 28;127(3296):471–471. doi: 10.1126/science.127.3296.471. [DOI] [PubMed] [Google Scholar]
  14. COTZIAS G. C., BORG D. C., HUGHES E. R., BERTINCHAMPS A., PAPAVASILIOU P. S. Phenothiazines: curative or causative in regard to parkinsonism? Rev Can Biol. 1961 Jun;20:289–294. [PubMed] [Google Scholar]
  15. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  16. ELLIOTT K. A. gamma-Aminobutyric acid and factor I. Rev Can Biol. 1958 Sep;17(3):367–388. [PubMed] [Google Scholar]
  17. FLOREY E., FLOREY E. Studies on the distribution of Factor I in mammalian brain. J Physiol. 1958 Dec 4;144(2):220–228. doi: 10.1113/jphysiol.1958.sp006096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. HARRIS G. W., JACOBSOHN D. Functional grafts of the anterior pituitary gland. Proc R Soc Lond B Biol Sci. 1952 Feb 28;139(895):263–276. doi: 10.1098/rspb.1952.0011. [DOI] [PubMed] [Google Scholar]
  19. JENKNER F. L., WARD A., Jr Bulbar reticular formation and tremor. AMA Arch Neurol Psychiatry. 1953 Oct;70(4):489–502. [PubMed] [Google Scholar]
  20. KAHLSON G. A place for histamine in normal physiology. Lancet. 1960 Jan 9;1(7115):67–71. doi: 10.1016/s0140-6736(60)92896-8. [DOI] [PubMed] [Google Scholar]
  21. KOPERA H., LAZARINI W. Zur Frage der zentralen Ubertragung afferenter Impulse. IV. Die Verteilung der Substanz P im Zentralnervensystem. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1953;219(3):214–222. [PubMed] [Google Scholar]
  22. MCGEER P. L., BOULDING J. E., GIBSON W. C., FOULKES R. G. Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA. 1961 Sep 9;177:665–670. doi: 10.1001/jama.1961.03040360001001. [DOI] [PubMed] [Google Scholar]
  23. NASHOLD B. S., Jr Analysis of physiologic changes after chemical and mechanical lesions of the globus pallidus and/or thalamus in persons with extrapyramidal disorders. Rev Can Biol. 1961 Jun;20:381–389. [PubMed] [Google Scholar]
  24. PARRATT J. R., WEST G. B. Tissue histamine and 5-hydroxytryptamine. J Physiol. 1956 May 28;132(2):40–1P. [PubMed] [Google Scholar]
  25. RINALDI F., HIMWICH H. E. The site of action of antiparkinson drugs. Confin Neurol. 1955;15(4):209–224. doi: 10.1159/000105362. [DOI] [PubMed] [Google Scholar]
  26. SACKS W. A cerebral decarboxylase for 5-hydroxytryptophane in humans. J Appl Physiol. 1961 Nov;16:1050–1054. doi: 10.1152/jappl.1961.16.6.1050. [DOI] [PubMed] [Google Scholar]
  27. SANO I., GAMO T., KAKIMOTO Y., TANIGUCHI K., TAKESADA M., NISHINUMA K. Distribution of catechol compounds in human brain. Biochim Biophys Acta. 1959 Apr;32:586–587. doi: 10.1016/0006-3002(59)90652-3. [DOI] [PubMed] [Google Scholar]
  28. UNNA K. R., VERNIER V. G. The experimental evaluation of antiparkinsonian compounds. Ann N Y Acad Sci. 1956 Nov 16;64(4):690–704. doi: 10.1111/j.1749-6632.1956.tb36841.x. [DOI] [PubMed] [Google Scholar]
  29. WHITE R. P., WESTERBEKE E. J. Differences in central anticholinergic actions of phenothiazine derivatives. Exp Neurol. 1961 Oct;4:317–329. doi: 10.1016/0014-4886(61)90058-9. [DOI] [PubMed] [Google Scholar]
  30. WHITE T. Formation and catabolism of histamine in brain tissue in vitro. J Physiol. 1959 Dec;149:34–42. doi: 10.1113/jphysiol.1959.sp006323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. ZETLER G., SCHLOSSER L. Uber die Verteilung von Substanz P und Cholinacetylase im Gehirn. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1955;224(2):159–175. [PubMed] [Google Scholar]
  32. ZETLER G. Substanz P, ein Polypeptid aus Darm und Gehirn mit depressiven, hyperalgetischen und Morphin-antagonistischen Wirkungen auf das Zentralnervensystem. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1956;228(6):513–538. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES